Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 3 - The Real Truth

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Barchart

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen Pulls Controversial Alzheimer's Drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

International Business Times

Patent monopolies are not "free" market

Drug patent monopolies cost each family $5,000 per year

Salon

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Do new Alzheimer's drugs actually help?

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Salon

FDA approves postpartum depression pill

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

Salon

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Zenger

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Axios

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Roll Call

Fortune 500 companies and CEOs react to end of affirmative action

Fortune 500 companies, including Salesforce and Microsoft, reacted to the Supreme Court's decision to reject affirmative action at U.S. colleges and universities.

Fortune

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data

June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserve’s interest rate decision while also awaiting crucial U.S. PPI data.

Barchart

Stocks Rally on Expectations the Fed Will Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IU XX) (QQQ ) closed up +0.79%. Stock indexes on Tuesday finished moderately higher, with the...

Barchart

Stocks Climb on the Outlook for the Fed to Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. U.S. stocks this morning are moderately higher, with the...

Axios

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

A Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer

Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.

The Independent UK

Drug for rare form of Lou Gehrig’s disease OK'd by FDA

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

Tribune News Service

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Chicago Tribune

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Tribune News Service

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

The Conversation

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

Asharq Al-Awsat

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

1 2 3 4 5

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.